Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

(2020) S. Depil et al.   NATURE REVIEWS DRUG DISCOVERY

First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.

(2020) Sattva Swarup Neelapu et al.   JOURNAL OF CLINICAL ONCOLOGY

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

(2020) Reuben Benjamin et al.   LANCET

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells

(2018) Saba Ghassemi et al.   Cancer Immunology Research

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

(2017) Waseem Qasim et al.   Science Translational Medicine

The Impact of Ex Vivo Clinical Grade Activation Protocols on Human T-cell Phenotype and Function for the Generation of Genetically Modified Cells for Adoptive Cell Transfer Therapy

(2010) Paul C. Tumeh et al.   JOURNAL OF IMMUNOTHERAPY